A scientific review on Eudragit RS 100 and RL 100 polymer blends for colon-specific oral nanoparticulate drug delivery system

Colon-targeted oral drug delivery offers significant therapeutic advantages for local and systemic treatment of diseases such as inflammatory bowel disease, Colorectal Cancer, and parasitic infections. This study investigates the potential of combining 'Eudragit RS 100' and 'RL 100' polymers in nanoparticulate drug delivery systems to achieve controlled and site-specific drug release in the colon. The two polymers are water-insoluble and pH-independent, and the amount of quaternary ammonium groups can be varied, thereby enabling adjustment of permeability and drug release rate. Tailored release profiles can be achieved by varying the RS: RL ratio to meet specific clinical needs. Using this combination, nanoparticles demonstrated improved encapsulation, inhibition of early drug degradation, mucoadhesion, and longer colonic retention. The clinical relevance and versatility of these polymeric systems are also evident, as disease-specific applications have been noted, including indications for ulcerative colitis, Crohn's disease, and Colorectal Cancer. Overall, the Eudragit mixture of RS and RL provides a compelling basis for developing colon-specific nanomedicine.